1. Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial. (25th November 2020) Authors: Ferrannini, G; Gerstein, H.C; Colhoun, H.M; Dagenais, G.R; Diaz, R; Dyal, L; Lakshmanan, M; Mellbin, L; Probstfield, J; Riddle, M.C; Shaw, J.E; Ryden, L Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗